Authors: Breitz, HB Weiden, PL Beaumier, PL Axworthy, DB Seiler, C Su, FM Graves, S Bryan, K Reno, JM

Citation: Hb. Breitz et al., Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and Y-90-DOTA-biotin, J NUCL MED, 41(1), 2000, pp. 131-140

Authors: Axworthy, DB Reno, JM Hylarides, MD Mallett, RW Theodore, LJ Gustavson, LM Su, FM Hobson, LJ Beaumier, PL Fritzberg, AR

Citation: Db. Axworthy et al., Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity, P NAS US, 97(4), 2000, pp. 1802-1807

Authors: Wilbert, SM Engrissei, G Yau, EK Grainger, DJ Tatalick, L Axworthy, DB

Citation: Sm. Wilbert et al., Quantitative analysis of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal standard, ANALYT BIOC, 278(1), 2000, pp. 14-21

Authors: Theodore, LJ Fritzberg, AR Schultz, JE Axworthy, DB

Citation: Lj. Theodore et al., Evolution of a pretarget radioimmunotherapeutic regimen, RADIOIMMUNOTHERAPY OF CANCER, 2000, pp. 195-221

Authors: Graves, SS Goshorn, SC Stone, DM Axworthy, DB Reno, JM Bottino, B Searle, S Henry, A Pedersen, J Rees, AR Libby, RT

Citation: Ss. Graves et al., Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody, CLIN CANC R, 5(4), 1999, pp. 899-908